Compare DexCom, Inc. (DXCM) vs Vanguard International High Dividend Yield ETF (VYMI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Vanguard International High Dividend Yield ETF — how do they compare? DexCom, Inc. trades at $83.98 (market cap $31.86B), while Vanguard International High Dividend Yield ETF trades at $100.4 (market cap $22.80B). The key difference: DexCom, Inc. is the larger of the two by market cap, and Vanguard International High Dividend Yield ETF is more actively traded (748,441 versus 3,607,070). Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Vanguard International High Dividend Yield ETF for 50 Days on average.
| DXCM | VYMI | |
|---|---|---|
Market Cap | $31.86B | $22.80B |
Volume | 3,607,070 | 748,441 |
Sector | Health | Broad Market / Factor |
52-Week High | $92.34 | $107.13 |
52-Week Low | $54.84 | $82.92 |
Typical Hold Time | 62 Days | 50 Days |
Enterprise Value | $31.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $84.03, down 0.32% on the day, with strong fundamental performance including three consecutive quarterly EPS beats and robust 20.12% net income margin. The stock shows bearish technical signals with price near pivot point support at $84, while analyst consensus remains overwhelmingly positive with 81% buy ratings and $95.07 price target representing 13% upside potential. Recent news highlights expansion opportunities in Type 2 diabetes care and executive promotions.
DXCM presents a compelling growth story with expanding profit margins and consistent earnings outperformance, though technical weakness and premium valuation create near-term headwinds. The company's leadership in continuous glucose monitoring and Type 2 diabetes market expansion provide long-term catalysts, while competition and reimbursement risks require monitoring.
VYMI trades at $100.27 with minimal daily movement (+0.04%). Technical indicators show a bearish trend with moving averages signaling caution, though oscillators are neutral. Recent news highlights institutional accumulation and positive performance comparisons to peers. The ETF's international high-dividend strategy focuses on financials, energy, and healthcare sectors.
Outlook remains mixed: bullish sentiment from media and institutional inflows contrasts with bearish technicals. Key opportunities include sector alignment with rising rates and attractive yield; risks involve global economic volatility and concentrated financial exposure. Investors should weigh dividend stability against technical weakness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Vanguard International High Dividend Yield ETF
VYMI is an index-based ETF that provides exposure to non-U.S. companies across developed and emerging markets that are characterized by high dividend yields. It tracks the FTSE All-World ex US High Dividend Yield Index, offering a diversified, low-cost way to capture international income while serving as a tactical hedge against U.S. market concentration.
Read more on VYMI →
